Bone marrow suppression

Onconova Therapeutics, Inc. and Trawsfynydd Therapeutics, Inc. Announce Business Combination to Form Traws Pharma, Inc, a Best-in-Class Virology and Oncology Company

Retrieved on: 
Tuesday, April 2, 2024
COVID19, COVID, Trawsfynydd, Pfizer, Drug, Novartis, General partnership, Patient, CYP, Oseltamivir, CDK, Aes, Ritonavir, SARS-CoV-2, Delta, Infection, Viral disease, Omicron, Therapy, OrbiMed, Safety, Pharmacokinetics, Toxicology, Lilly, Bone marrow suppression, CSO, GLP, Mergers and acquisitions, Pharmaceutical industry

Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)

Key Points: 
  • Combined board to be led by Executive Chairman Iain Dukes DPhil (OrbiMed) along with Nikolay Savchuk, Ph.D. (Torrey Pines)
    Companies to host joint webcast, April 2, 2024 at 8:30 a.m.
  • Under the terms of the agreement, Onconova acquired 100% of Trawsfynydd’s outstanding equity interests.
  • These proceeds will be used to advance the Traws’ programs through multiple clinical data catalysts and complete the dose ranging study for narazaciclib.
  • Topline data are expected H2 2024
    Phase 2 study planned to be initiated in H2 2024.

CTLA4 (Cytotoxic T-Lymphocyte-Associated Protein 4) Inhibitors Market to grow by USD 2.23 billion between 2023 and 2028, growth Driven by High target affinity and specificity of CTLA4 inhibitors - Technavio

Retrieved on: 
Friday, January 26, 2024
Bristol Myers Squibb, Cytotoxicity, Research, Incidence, Melanoma, ROW, Biotechnology, AstraZeneca, Ipilimumab, HDAC, Carcinoma, Bone marrow suppression, Growth, BioNTech, Bio-Techne, NSCLC, Combination therapy, Investment, Disease, BMS, USD, FDA, Diarrhea, HBM, Hair loss, Merck, CTLA4, Immune system, Pharmaceutical industry

NEW YORK, Jan. 25, 2024 /PRNewswire/ -- The CTLA4 (cytotoxic t-lymphocyte-associated protein 4) inhibitors market is estimated to grow by USD 2.23 billion from  2023 to 2028, growing at a CAGR of 15.11%. High target affinity and specificity of CTLA4 inhibitors are notably driving the growth. Despite several approved therapies, the treatment landscape for advanced or recurrent cancer lacks sufficient drug responsiveness. Available therapies often lead to severe side effects, reducing patient compliance. Chemotherapy, the current standard of care for advanced cancers, causes significant adverse effects like bone marrow suppression, diarrhea, and hair loss. Similarly, surgery and radiation therapy have limitations in treating recurring carcinomas like melanomas. Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.

Key Points: 
  • High target affinity and specificity of CTLA4 inhibitors are notably driving the growth.
  • Furthermore, CTLA4 inhibitors work by enhancing the immune system, resulting in comparatively fewer associated side effects than traditional oncology treatments.
  • The global proteasome inhibitors market size is estimated to grow by USD 2.91 billion at a CAGR of 7.48% between 2023 and 2028.
  • The HDAC (histone deacetylase) inhibitors market is estimated to grow at a CAGR of 7.73% between 2022 and 2027.

Endo Launches Colchicine Capsules, Generic Version of MITIGARE®

Retrieved on: 
Thursday, November 2, 2023
Aplastic anemia, Patient, Abdominal pain, Clarithromycin, Food, Fatal, Thrombocytopenia, Vomiting, Diarrhea, OTC, Colchicine, Endo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nausea, Bone marrow suppression, Endo International, Senior, Ciclosporin, Rhabdomyolysis, Risk, Capsule, Leukopenia, Pancytopenia, Safety, Pain, Granulocyte, Death, Pharmaceutical industry, Dairy, Dietary supplement, CYP3A4

DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.

Key Points: 
  • DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.
  • This is the first generic colchicine capsule approved by the U.S. Food and Drug Administration.
  • Patients with renal or hepatic impairment should not be given colchicine with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors.
  • Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity.

Endo Launches Colchicine Capsules, Generic Version of MITIGARE®

Retrieved on: 
Thursday, November 2, 2023
Aplastic anemia, Patient, Abdominal pain, Clarithromycin, Food, Fatal, Thrombocytopenia, Vomiting, Diarrhea, OTC, Colchicine, Endo, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Nausea, Bone marrow suppression, Endo International, Senior, Ciclosporin, Rhabdomyolysis, Risk, Capsule, Leukopenia, Pancytopenia, Safety, Pain, Granulocyte, Death, Pharmaceutical industry, Dairy, Dietary supplement, CYP3A4

DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.

Key Points: 
  • DUBLIN, Nov. 2, 2023 /PRNewswire/ -- Endo International plc (OTC: ENDPQ) announced today that one of its operating companies, Par Pharmaceutical, Inc., has begun shipping colchicine 0.6 mg capsules, a generic version of Hikma's MITIGARE®.
  • This is the first generic colchicine capsule approved by the U.S. Food and Drug Administration.
  • Patients with renal or hepatic impairment should not be given colchicine with drugs that inhibit both P-glycoprotein and CYP3A4 inhibitors.
  • Combining these dual inhibitors with colchicine in patients with renal or hepatic impairment has resulted in life-threatening or fatal colchicine toxicity.

G1 Therapeutics Announces Upcoming Presentations at the 2023 ASCO Quality Care Symposium

Retrieved on: 
Monday, October 16, 2023
King Fahad Specialist Hospital Dammam, Abstract, Research, Society, American Society of Clinical Oncology, RESEARCH, AM, Cytopenia, Therapy, G1 Therapeutics, Patient, PARK, ASCO, Pharmaceutical industry, Medical imaging, Flour, Bone marrow suppression

RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA.

Key Points: 
  • RESEARCH TRIANGLE PARK, N.C., Oct. 16, 2023 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX ), a commercial-stage oncology company, today announced that multiple abstracts have been accepted for poster presentation at the upcoming 2023 American Society of Clinical Oncology (ASCO) Quality Care Symposium, held October 27th and 28th in Boston, MA.
  • A copy of the posters will be made available on the G1 Therapeutics website following the presentations here .
  • “The important research being presented at this year’s ASCO Quality Care Symposium highlights the significant burden of chemotherapy-induced myelosuppression and the real-world clinical impact of treatment with trilaciclib in patients with extensive-stage small cell lung cancer," said Raj Malik, M.D., Chief Medical Officer of G1 Therapeutics.
  • Burden of Myelosuppression in Extensive-Stage Small-Cell Lung Cancer Patients Receiving Chemotherapy: Retrospective Analysis of Real-World Data from Tennessee Oncology.

Global Doxorubicin Market Report 2023: Growing Demand for Effective Cancer Treatments Fuels the Sector - ResearchAndMarkets.com

Retrieved on: 
Thursday, June 8, 2023
Pharmaceutical, Health, Oncology, Doxorubicin, DNA, Streptomyces, Cell death, Hair loss, Multiple myeloma, Bone marrow suppression, Cancer, Lung cancer, Bladder cancer, Immunotherapy, Cardiotoxicity, USD, Vomiting, DNA replication, Stomach cancer, Incidence, Anthracycline, Patient, Risk, B-cell lymphoma, Hodgkin lymphoma, Nausea, Growth, Ovarian cancer, Thyroid cancer, Breast cancer, Mouth ulcer, Extrusion, Pharmaceutical industry

The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Global Doxorubicin Market Report and Forecast 2023-2031" report has been added to ResearchAndMarkets.com's offering.
  • The global doxorubicin market size attained a value of USD 1218 million in 2022.
  • [Doxorubicin is used primarily in the treatment of a wide range of cancers, including breast cancer, ovarian cancer, lung cancer, stomach cancer, thyroid cancer, bladder cancer, multiple myeloma, Hodgkin's lymphoma, and non-Hodgkin's lymphomas.
  • The global market for doxorubicin is expected to continue to grow in the coming years, driven by an increasing incidence of cancer and a growing demand for effective treatments.

Artiva Biotherapeutics Presents Initial Data from First-in-Human Phase 1/2 Clinical Trial of AB-101 at the 2023 ASCO Annual Meeting

Retrieved on: 
Thursday, May 25, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Complete Response Letter, Rituximab, Graft-versus-host disease, Northwest Biotherapeutics, Febrile neutropenia, CRS, Umbilical cord, Cyclophosphamide, NK, Toxicity, Șaeș, ASCO, Combination therapy, Bone marrow suppression, American Society of Clinical Oncology, Patient, Standard of care, Cytopenia, Annual general meeting, Steroid, Symantec Endpoint Protection, Partial-response maximum-likelihood, Society, Neurotoxicity, ORR, Safety, Vaccine, Pharmaceutical industry, Fever

Artiva Biotherapeutics, Inc. , a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.

Key Points: 
  • Artiva Biotherapeutics, Inc. , a clinical stage company whose mission is to deliver highly effective, off-the-shelf, allogeneic natural killer (NK) cell-based therapies, announced today the presentation of initial data from the dose-escalation stage of its ongoing Phase 1/2 clinical trial of AB-101.
  • The presentation will take place on Monday, June 5, during the 2023 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago.
  • Myelosuppression, consistent with standard lymphodepletion regimens, was the most common Grade ≥ 3 toxicity, but was manageable with standard of care.
  • In the combination cohort, only one unrelated Grade 3 SAE of pyrexia was noted.​ There were no treatment-related AEs leading to discontinuation of AB-101.​

New Study Confirms Consistent Risk of Myelosuppression Across All Patients Receiving Chemotherapy for Small Cell Lung Cancer

Retrieved on: 
Tuesday, May 16, 2023
Neutropenia, Carcinoma, Medical Affairs Bureau, Providence St. Joseph Health, G1 Therapeutics, EMR, ISPOR, Pharmacoeconomics, Aplastic anemia, Patient, SCLC, RESEARCH, Bone marrow suppression, Risk, ECOG, Anemia, Diagnosis, Poster, Cornerstone, Therapy, Death, Thrombocytopenia, International Society, PARK, Medical imaging

“Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens,” said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics.

Key Points: 
  • “Chemotherapy remains an effective cornerstone treatment for patients with small cell lung cancer; unfortunately, chemotherapy-induced myelosuppression is a known common and debilitating complication associated with these cytotoxic regimens,” said Norman Nagl, Ph.D., Vice President of Medical Affairs at G1 Therapeutics.
  • The poster, titled, “An Analysis of Patient Characteristics Associated With Myelosuppression Among Small Cell Lung Cancer Patients Treated in US Community Cancer Care Practices” is available in the scientific publications section of G1’s website.
  • Adult patients diagnosed with SCLC who received chemotherapy between 2016 and 2018 and had longitudinal laboratory data were included in this study.
  • In addition, multivariate logistic regressions were conducted to examine association between patient characteristics and risk of myelosuppression in each lineage (anemia, neutropenia, thrombocytopenia).

Tango Therapeutics Reports First Quarter 2023 Financial Results and Provides Business Highlights

Retrieved on: 
Tuesday, May 9, 2023
PK, SDMA, MTAP, AACR, GBM, Repressor, MTA, Bone marrow suppression, Therapeutic index, Clinical trial, Pharmacokinetics, Mutation, Traffic barrier, Histology, Fast Track, Breast, NSCLC, STK11, Carcinoma, Tango, Glioblastoma, PRMT5, Research and development, RCOR1, American Association for Cancer Research, Patient, Cancer, Annual general meeting, Neoplasm, Infrared spectroscopy correlation table, FDA, Pembrolizumab, Collaboration, Therapy, IND, FTD, Safety, Pharmaceutical industry, Vaccine, Research

BOSTON, May 09, 2023 (GLOBE NEWSWIRE) -- Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering and delivering the next generation of precision cancer medicines, reported its financial results for the first quarter ended March 31, 2023, and provided business highlights.

Key Points: 
  • We look forward to providing additional data from the trial in 2024,” said Barbara Weber, M.D., President and Chief Executive Officer of Tango Therapeutics.
  • TNG908 proof-of-mechanism as an MTA-cooperative PRMT5 inhibitor demonstrated by marked SDMA reduction in MTAP-deleted cancer cells versus normal tissue.
  • The TNG462 Investigational New Drug (IND) application cleared in January 2023, and the first patient is expected to be dosed in mid-2023.
  • General and administrative expenses were $8.0 million for the three months ended March 31, 2023, compared to $6.8 million for the same period in 2022.

New Study Evaluates Effects of Chemotherapy-Induced Myelosuppression for Extensive-Stage Small Cell Lung Cancer, Data from Florida Cancer Specialists & Research Institute

Retrieved on: 
Thursday, April 13, 2023
Neutropenia, Senior, Patient, FACP, American Society of Clinical Oncology, Bone marrow, Lung cancer, Aplastic anemia, Doctor of Philosophy, Pharmacist, SCLC, ASCO, Bone marrow suppression, Lymphocytopenia, G1 Therapeutics, Leukopenia, Risk, Anemia, Data, Thrombocytopenia, Society, FCS, Medical imaging, Medical device, MD

FORT MYERS, Fla., April 13, 2023 /PRNewswire/ -- A new study using data from Florida Cancer Specialists & Research Institute, LLC (FCS) evaluates the effects of chemotherapy-induced myelosuppression for extensive-state small cell lung cancer (ES-SCLC) in a real-world community oncology setting.

Key Points: 
  • FORT MYERS, Fla., April 13, 2023 /PRNewswire/ -- A new study using data from Florida Cancer Specialists & Research Institute, LLC (FCS) evaluates the effects of chemotherapy-induced myelosuppression for extensive-state small cell lung cancer (ES-SCLC) in a real-world community oncology setting.
  • The study, "Burden of chemotherapy-induced myelosuppression among patients with extensive-stage small cell lung cancer: A retrospective study from community oncology practices," was done in support of G1 Therapeutics and in collaboration with Xcenda.
  • ES-SCLC, considered a more aggressive form of metastatic small cell lung cancer, utilizes chemotherapy as a first-line treatment.
  • Patients experiencing myelosuppression are also at risk for developing additional medical issues resulting in delays in chemotherapy treatment until the myelosuppression is under control.